Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QEEG cordance and EEG connectivity changes after subanesthetic ketamine in depressive disorder
2009-010625-39Phase 3Completed
- Sponsor
- National Institute of Mental Health
- Start
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of ketamine in major depressive disorder (MDD), sponsored by National Institute of Mental Health. Primary endpoints: Predictive value of prefrontal QEEG theta cordance for antidepressant response and Changes in functional brain connectivity during remission. Started Feb 2010; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2009-010625-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010625-39.